Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium-177 rhPSMA-10.1 vs Pluvicto in metastatic prostate cancer
NCT06516510Phase 1Terminated
- Sponsor
- Blue Earth Therapeutics
- Start
- Oct 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of lutetium-177 rhPSMA-10.1 in Metastatic Prostate Cancer (mPC) (2 arms), sponsored by Blue Earth Therapeutics. Primary endpoint: Ratio of Kidney and Tumor Absorbed Doses at 12 weeks. Started Oct 2024; status: terminated.
02
Drugs
lutetium-177 rhPSMA-10.1
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT06516510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516510.